Company news
Bioxcel Therapeutics, Inc. (NASDAQ:BTAI) news
Bioxcel Therapeutics, Inc. news releases on 6ix. Latest, Nov 12, 2020: BioXcel Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business…
Press releases — page 4
BioXcel Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update
November 11, 2020
BioXcel Therapeutics Announces Completion of Pre-NDA Meeting with FDA for BXCL501 for the Acute Treatment of Agitation in Patients with Schizophrenia and Bipolar Disorders
November 10, 2020
BioXcel Therapeutics Receives FDA Clearance of IND for Phase 2 Trial with BXCL501 for the Treatment of Agitation Associated with Delirium
October 25, 2020
BioXcel Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Update
August 13, 2020
BioXcel Therapeutics Announces Primary and Secondary Endpoints Met in Two Pivotal Phase 3 Trials of BXCL501 for the Acute Treatment of Agitation in Patients with Schizophrenia and Bipolar Disorder
July 19, 2020
BioXcel Therapeutics Announces Compassionate Use Program at Massachusetts General Hospital for BXCL501 to Treat COVID-19 Patients Suffering from Delirium and Agitation
July 8, 2020
BioXcel Therapeutics Announces Notice of Allowance for U.S. Patent Application Covering Formulation for BXCL501 and Methods of Treating Agitation
July 6, 2020
BioXcel Therapeutics Announces Appointment of Reina Benabou, M.D., Ph.D., as Chief Development Officer
June 22, 2020
BioXcel Therapeutics Announces Appointment of William P. Kane as Chief Commercial Officer
June 15, 2020
BioXcel Therapeutics Announces First Patient Enrolled in Phase 1b/2 RELEASE Trial of BXCL501 for the Treatment of Opioid Withdrawal Symptoms
June 10, 2020
BioXcel Therapeutics Announces Completion of Patient Enrollment in Phase 3 SERENITY Trials with BXCL501
May 13, 2020
BioXcel Therapeutics Reports First Quarter 2020 Financial Results and Provides Business Update
May 11, 2020
BioXcel Therapeutics Announces Initiation of a Phase 2 Study of BXCL701 in Combination with a PD-1 Inhibitor for Treatment Emergent Neuroendocrine Prostate Cancer
April 27, 2020
BioXcel Therapeutics Provides an Update on its Ongoing Phase 3 SERENITY Trials
March 18, 2020
BioXcel Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update
March 8, 2020
BioXcel Therapeutics Announces Initiation of a Phase 2 Study Designed to Assess Agitation-Associated Biomarkers and their Response to BXCL501
February 17, 2020
BioXcel Therapeutics Announces FDA Clearance of IND Application for BXCL501 for the Treatment of Opioid Withdrawal Symptoms
February 4, 2020
BioXcel Therapeutics Announces First Patient Enrolled in Phase 1b/2 Study of BXCL501 for Acute Treatment of Agitation Associated with Dementia
January 6, 2020
BioXcel Therapeutics Announces Initiation of Pivotal Phase 3 Studies of BXCL501 for Acute Treatment of Agitation in Patients with Schizophrenia and Bipolar Disorder
December 29, 2019
BioXcel Therapeutics to Expand Study of BXCL701 into Multiple Advanced Solid Tumor Types
December 10, 2019
BioXcel Therapeutics Prepares to Initiate Pivotal Phase 3 Studies with BXCL501 Following Positive End-of-Phase 2 Meeting with FDA
December 2, 2019
BioXcel Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Update
November 13, 2019
BioXcel Therapeutics Announces BXCL501 Program Initiative for Prevention and Treatment of Acute Agitation using Wearable Digital Devices
September 17, 2019